Cambium Bio Limited
CMB
Clasificación en acciones
#32501
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Precio por acción
$0.31737816
Capitalización bursátil
$9.34M
Cambio (1 día)
0.00%
Cambio (1 año)
5,917.33%
País
AU
Comercio Cambium Bio Limited (CMB)
Categoría
Healthcare
Ratio P/B de Cambium Bio Limited (CMB)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Cambium Bio Limited, el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Cambium Bio Limited desde 2026 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| 6.1824 | - |
NL
|
|
| - | - |
CH
|
